サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1409188

アンジオテンシン受容体拮抗薬（ARB）の世界市場レポート 2024年

Angiotensin Receptor Blockers (ARBs) Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
アンジオテンシン受容体拮抗薬（ARB）の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

アンジオテンシン受容体拮抗薬（ARB）の市場規模は近年着実に成長しています。2023年の82億6,000万米ドルから2024年には86億2,000万米ドルへと、CAGR4.3％で拡大します。この成長には、高血圧の蔓延、アンジオテンシン受容体拮抗薬の臨床的有効性の実証、心血管疾患の負担の増加、ARBによる腎保護、臨床ガイドラインにおけるARBの第一選択薬としての採用、これらの薬剤の費用対効果の認識など、いくつかの要因が挙げられます。これらの要因が総合的に、さまざまな病状の管理におけるアンジオテンシン受容体拮抗薬の実績と採用に寄与しました。

2023年のアンジオテンシン受容体拮抗薬市場シェアでは北米が最大地域でした。当レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 アンジオテンシン受容体拮抗薬市場の特徴

第3章 アンジオテンシン受容体拮抗薬の市場動向と戦略

第4章 アンジオテンシン受容体拮抗薬市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界のアンジオテンシン受容体拮抗薬市場規模と成長

  • 世界のアンジオテンシン受容体拮抗薬市場促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のアンジオテンシン受容体拮抗薬の市場規模実績と成長、2018-2023
  • 世界のアンジオテンシン受容体拮抗薬市場規模と成長予測、2023-2028、2033年

第6章 アンジオテンシン受容体拮抗薬市場セグメンテーション

  • 世界のアンジオテンシン受容体拮抗薬市場、製品別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • バルサルタン
    • テルミサルタン
    • ロサルタン
    • イルベサルタン
    • アジルサルタン
    • オルメサルタン
  • 世界のアンジオテンシン受容体拮抗薬市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • 高血圧
    • 心血管疾患
    • 腎臓病
    • その他の用途
  • 世界のアンジオテンシン受容体拮抗薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
    • 病院
    • 専門クリニック
    • 外来手術センター

第7章 アンジオテンシン受容体拮抗薬市場の地域および国分析

  • 世界のアンジオテンシン受容体拮抗薬市場、地域別、実績および予測、2018-2023、2023-2028、2033年
  • 世界のアンジオテンシン受容体拮抗薬市場、国別、実績および予測、2018-2023、2023-2028、2033年

第8章 アジア太平洋のアンジオテンシン受容体拮抗薬市場

第9章 中国のアンジオテンシン受容体拮抗薬市場

第10章 インドのアンジオテンシン受容体拮抗薬市場

第11章 日本のアンジオテンシン受容体拮抗薬市場

第12章 オーストラリアのアンジオテンシン受容体拮抗薬市場

第13章 インドネシアのアンジオテンシン受容体拮抗薬市場

第14章 韓国のアンジオテンシン受容体拮抗薬市場

第15章 西欧のアンジオテンシン受容体拮抗薬市場

第16章 英国のアンジオテンシン受容体拮抗薬市場

第17章 ドイツのアンジオテンシン受容体拮抗薬市場

第18章 フランスのアンジオテンシン受容体拮抗薬市場

第19章 イタリアのアンジオテンシン受容体拮抗薬市場

第20章 スペインのアンジオテンシン受容体拮抗薬市場

第21章 東欧のアンジオテンシン受容体拮抗薬市場

第22章 ロシアのアンジオテンシン受容体拮抗薬市場

第23章 北米のアンジオテンシン受容体拮抗薬市場

第24章 米国のアンジオテンシン受容体拮抗薬市場

第25章 カナダのアンジオテンシン受容体拮抗薬市場

第26章 南米アンジオテンシン受容体拮抗薬市場

第27章 ブラジルのアンジオテンシン受容体拮抗薬市場

第28章 中東のアンジオテンシン受容体拮抗薬市場

第29章 アフリカのアンジオテンシン受容体拮抗薬市場

第30章 アンジオテンシン受容体拮抗薬市場の競合情勢と企業プロファイル

  • アンジオテンシン受容体拮抗薬市場の競合情勢
  • アンジオテンシン受容体拮抗薬市場企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • Merck &Co. Inc.
    • AstraZeneca Plc.
    • Bristol-Myers Squibb Company

第31章 世界のアンジオテンシン受容体拮抗薬市場の競合ベンチマーキング

第32章 世界のアンジオテンシン受容体拮抗薬市場競争ダッシュボード

第33章 アンジオテンシン受容体拮抗薬市場における主要な合併と買収

第34章 アンジオテンシン受容体拮抗薬市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10726

“Angiotensin Receptor Blockers (ARBs) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angiotensin receptor blockers (abs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for angiotensin receptor blockers (abs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The angiotensin receptor blockers (abs) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Valsartan; Telmisartan; Losartan; Irbesartan; Azilsartan; Olmesartan
  • 2) By Application: Hypertension; Cardiovascular Diseases; Kidney Diseases; Other Applications
  • 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
  • Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca Plc.; Bristol-Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Angiotensin receptor blockers (ARBs) are medications designed to widen blood vessels, addressing conditions such as high blood pressure (hypertension), heart failure, and kidney disease, particularly in individuals with diabetes. These drugs work by blocking the effects of angiotensin, a chemical in the body that causes blood vessels to constrict, leading to increased blood pressure and added strain on the heart.

The primary products within the class of angiotensin receptor blockers (ARBs) include valsartan, losartan, irbesartan, azilsartan, and olmesartan. Losartan, for instance, is an ARB that not only treats hypertension but also reduces the risk of stroke and manages diabetic nephropathy. These medications find applications in various medical conditions, such as hypertension, cardiovascular diseases, kidney diseases, among others, and are utilized by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

The angiotensin receptor blockers (ARBs) market research report is one of a series of new reports from The Business Research Company that provides angiotensin receptor blockers (ARBs) market statistics, including angiotensin receptor blockers (ARBs) industry global market size, regional shares, competitors with a angiotensin receptor blockers (ARBs) market share, detailed angiotensin receptor blockers (ARBs) market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (ARBs) industry. This angiotensin receptor blockers (ARBs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angiotensin receptor blockers (arbs) market size has grown steadily in recent years. It will grow from $8.26 billion in 2023 to $8.62 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed during the historical period can be attributed to several factors, including the widespread prevalence of the hypertension epidemic, the demonstrated clinical efficacy of angiotensin receptor blockers (ARBs), the increasing burden of cardiovascular diseases, the renal protection offered by ARBs, the inclusion of ARBs as a first-line treatment in clinical guidelines, and the recognition of the cost-effectiveness of these medications. These factors collectively contributed to the historical growth and adoption of angiotensin receptor blockers in managing various medical conditions.

The angiotensin receptor blockers (arbs) market size is expected to see steady growth in the next few years. It will grow to $10.28 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of precision medicine approaches, a focus on combination therapies for improved treatment outcomes, the global expansion of the market for angiotensin receptor blockers (ARBs), the development of biomarker-based treatment strategies, government initiatives supporting hypertension management, and an increased awareness of hypertension and its complications. Key trends expected in the forecast period encompass the widespread adoption of telemedicine, increased investments in research and development, the impact of generic competition and patent expirations, the integration of digital health solutions for medication adherence, and the growing influence of biosimilar competition in the pharmaceutical landscape.

The rising prevalence of cardiovascular diseases is anticipated to drive the expansion of the angiotensin receptor blockers market in the foreseeable future. Cardiovascular diseases (CVD) encompass various conditions affecting the heart or blood vessels, often associated with factors such as atherosclerosis and an augmented risk of blood clot formation. Angiotensin receptor blockers function by reducing blood pressure and enhancing the heart's pumping ability through the relaxation of veins and arteries. This mechanism aids in minimizing the risk of cardiovascular diseases. Notably, projections by the American College of Cardiology in August 2022 indicate a substantial surge in cardiovascular risk factors and disease rates within the United States by 2060. Consequently, the increased incidence of cardiovascular diseases stands as a significant driver behind the growth of the angiotensin receptor blockers market.

The escalating prevalence of chronic kidney diseases is poised to fuel the growth trajectory of the angiotensin receptor blockers market in the coming years. Chronic kidney disease (CKD) denotes a prolonged condition marked by a gradual decline in kidney function. Angiotensin receptor blockers (ARBs) play a vital role in managing CKD by reducing blood pressure, providing renal protection, addressing diabetic nephropathy, and managing associated cardiovascular complications. Statistics from the Centers for Disease Control and Prevention in July 2022 revealed that approximately 15% or 37 million individuals in the United States were affected by kidney disease. Additionally, data from the Australian Institute of Health and Welfare showcased an increasing prevalence of kidney replacement therapy from 2019 to 2020, underscoring the growing burden of chronic kidney diseases. This escalating prevalence of CKD serves as a significant catalyst driving the expansion of the angiotensin receptor blockers market.

The escalating prevalence of hypertension diseases is poised to drive the expansion of the angiotensin receptor blockers (ARBs) market in the foreseeable future. Hypertension, characterized by persistently elevated blood pressure, finds treatment through medications such as angiotensin receptor blockers (ARBs), which operate by widening blood arteries, facilitating smoother blood flow. This increased prevalence of hypertension among the populace is expected to heighten the demand for angiotensin receptor blockers. For instance, data from the Centers for Disease Control and Prevention (CDC) in July 2023 highlighted hypertension as a leading cause of mortality in the US, accounting for 691,095 fatalities in 2021. Approximately 47% of US adults, totaling 116 million individuals, suffer from hypertension, with only 24% having it under control. An estimated 34 million individuals recommended medication may necessitate prescription initiation, emphasizing the substantial demand for treatment. This data underscores how the rising prevalence of hypertension diseases is fueling the growth of the angiotensin receptor blockers (ARBs) market.

Innovation stands as a pivotal trend propelling the popularity of products within the angiotensin receptor blockers market. Key industry players are keenly focused on developing groundbreaking solutions to bolster their market standing. Notably, in February 2021, Novartis AG, a Switzerland-based pharmaceutical giant, introduced Entresto (sacubitril/valsartan). This medication received an expanded indication from the United States Food and Drug Administration (FDA) to mitigate the risk of cardiovascular death and hospitalization among adult patients grappling with chronic heart failure. The clinical benefits of Entresto are particularly notable among individuals with lower-than-normal left ventricular ejection fraction (LVEF). It stands as the inaugural and solitary therapy sanctioned in the US for guideline-defined heart failure, encompassing both heart failure with reduced ejection fraction (HFrEF) and a substantial segment of heart failure with preserved ejection fraction (HFpEF) patients.

Major market contenders within the angiotensin receptor blockers (ARBs) domain are channeling their efforts toward innovation and securing approvals to fortify their market presence. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, serves as a medication targeted at heart failure treatment. In January 2021, Merck, a Germany-based pharmaceutical entity, attained approval from the U.S. Food and Drug Administration (FDA) for VERQUVO (vericiguat). VERQUVO is indicated for treating heart failure with reduced ejection fraction (HFrEF) in adult patients. This medication aids in vasodilation, reducing cardiac strain, and enhancing cardiac function, signifying a noteworthy advancement in heart failure management.

Major companies operating in the angiotensin receptor blockers (arbs) market report are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Movianto, Clinical Trial Logistics, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma .

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2023. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the angiotensin receptor blockers (arbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The angiotensin receptor blockers (ARBs) market consists of sales of candesartan and eprosartan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Angiotensin Receptor Blockers (ARBs) Market Characteristics

3. Angiotensin Receptor Blockers (ARBs) Market Trends And Strategies

4. Angiotensin Receptor Blockers (ARBs) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Angiotensin Receptor Blockers (ARBs) Market Size and Growth

  • 5.1. Global Angiotensin Receptor Blockers (ARBs) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Angiotensin Receptor Blockers (ARBs) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Angiotensin Receptor Blockers (ARBs) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Angiotensin Receptor Blockers (ARBs) Market Segmentation

  • 6.1. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Valsartan
  • Telmisartan
  • Losartan
  • Irbesartan
  • Azilsartan
  • Olmesartan
  • 6.2. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hypertension
  • Cardiovascular Diseases
  • Kidney Diseases
  • Other Applications
  • 6.3. Global Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

7. Angiotensin Receptor Blockers (ARBs) Market Regional And Country Analysis

  • 7.1. Global Angiotensin Receptor Blockers (ARBs) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Angiotensin Receptor Blockers (ARBs) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market

  • 8.1. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Angiotensin Receptor Blockers (ARBs) Market

  • 9.1. China Angiotensin Receptor Blockers (ARBs) Market Overview
  • 9.2. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Angiotensin Receptor Blockers (ARBs) Market

  • 10.1. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Angiotensin Receptor Blockers (ARBs) Market

  • 11.1. Japan Angiotensin Receptor Blockers (ARBs) Market Overview
  • 11.2. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Angiotensin Receptor Blockers (ARBs) Market

  • 12.1. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Angiotensin Receptor Blockers (ARBs) Market

  • 13.1. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Angiotensin Receptor Blockers (ARBs) Market

  • 14.1. South Korea Angiotensin Receptor Blockers (ARBs) Market Overview
  • 14.2. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Angiotensin Receptor Blockers (ARBs) Market

  • 15.1. Western Europe Angiotensin Receptor Blockers (ARBs) Market Overview
  • 15.2. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Angiotensin Receptor Blockers (ARBs) Market

  • 16.1. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Angiotensin Receptor Blockers (ARBs) Market

  • 17.1. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Angiotensin Receptor Blockers (ARBs) Market

  • 18.1. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Angiotensin Receptor Blockers (ARBs) Market

  • 19.1. Italy Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Angiotensin Receptor Blockers (ARBs) Market

  • 20.1. Spain Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market

  • 21.1. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market Overview
  • 21.2. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Angiotensin Receptor Blockers (ARBs) Market

  • 22.1. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Angiotensin Receptor Blockers (ARBs) Market

  • 23.1. North America Angiotensin Receptor Blockers (ARBs) Market Overview
  • 23.2. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Angiotensin Receptor Blockers (ARBs) Market

  • 24.1. USA Angiotensin Receptor Blockers (ARBs) Market Overview
  • 24.2. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Angiotensin Receptor Blockers (ARBs) Market

  • 25.1. Canada Angiotensin Receptor Blockers (ARBs) Market Overview
  • 25.2. Canada Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Angiotensin Receptor Blockers (ARBs) Market

  • 26.1. South America Angiotensin Receptor Blockers (ARBs) Market Overview
  • 26.2. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Angiotensin Receptor Blockers (ARBs) Market

  • 27.1. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Angiotensin Receptor Blockers (ARBs) Market

  • 28.1. Middle East Angiotensin Receptor Blockers (ARBs) Market Overview
  • 28.2. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Angiotensin Receptor Blockers (ARBs) Market

  • 29.1. Africa Angiotensin Receptor Blockers (ARBs) Market Overview
  • 29.2. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Angiotensin Receptor Blockers (ARBs) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape And Company Profiles

  • 30.1. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape
  • 30.2. Angiotensin Receptor Blockers (ARBs) Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca Plc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bristol-Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Angiotensin Receptor Blockers (ARBs) Market Competitive Benchmarking

32. Global Angiotensin Receptor Blockers (ARBs) Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Angiotensin Receptor Blockers (ARBs) Market

34. Angiotensin Receptor Blockers (ARBs) Market Future Outlook and Potential Analysis

  • 34.1 Angiotensin Receptor Blockers (ARBs) Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Angiotensin Receptor Blockers (ARBs) Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Angiotensin Receptor Blockers (ARBs) Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer